| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
I-Mab (NASDAQ: IMAB)
IMAB Technical Analysis
5
| As on 9th Jun 2023 IMAB STOCK Price closed @ 3.14 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 14.80 & Strong Sell for SHORT-TERM with Stoploss of 32.45 we also expect STOCK to react on Following IMPORTANT LEVELS. |
IMABSTOCK Price
| Open | 3.22 | Change | Price | % |
| High | 3.22 | 1 Day | -0.04 | -1.26 |
| Low | 3.10 | 1 Week | -0.04 | -1.26 |
| Close | 3.14 | 1 Month | 0.18 | 6.08 |
| Volume | 174800 | 1 Year | -44.58 | -93.42 |
| 52 Week High 49.00 | 52 Week Low 2.95 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| IMAB Daily Charts |
IMAB Intraday Charts |
Whats New @ Bazaartrend |
IMAB Free Analysis |
|
|
IMAB Important Levels Intraday
| RESISTANCE | 3.37 |
| RESISTANCE | 3.30 |
| RESISTANCE | 3.25 |
| RESISTANCE | 3.21 |
| SUPPORT | 3.07 |
| SUPPORT | 3.03 |
| SUPPORT | 2.98 |
| SUPPORT | 2.91 |
IMAB Forecast May 2024
| 4th UP Forecast | 47.87 |
| 3rd UP Forecast | 33.52 |
| 2nd UP Forecast | 24.66 |
| 1st UP Forecast | 15.79 |
| 1st DOWN Forecast | -9.51 |
| 2nd DOWN Forecast | -18.38 |
| 3rd DOWN Forecast | -27.24 |
| 4th DOWN Forecast | -41.59 |
IMAB Weekly Forecast
| 4th UP Forecast | 12.49 |
| 3rd UP Forecast | 9.49 |
| 2nd UP Forecast | 7.64 |
| 1st UP Forecast | 5.78 |
| 1st DOWN Forecast | 0.50 |
| 2nd DOWN Forecast | -1.36 |
| 3rd DOWN Forecast | -3.21 |
| 4th DOWN Forecast | -6.21 |
IMAB Forecast2024
| 4th UP Forecast | 93.46 |
| 3rd UP Forecast | 64.49 |
| 2nd UP Forecast | 46.59 |
| 1st UP Forecast | 28.68 |
| 1st DOWN Forecast | -22.4 |
| 2nd DOWN Forecast | -40.31 |
| 3rd DOWN Forecast | -58.21 |
| 4th DOWN Forecast | -87.18 |
I-Mab ( NASDAQ USA Symbol : IMAB )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
IMAB Business Profile
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers. Its product candidates in pre-clinical development stage comprises TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM antibodies for treating oncology diseases. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; and PT Kalbe Genexine Biologics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China. Address: West Tower, OmniVision, Shanghai, China, 201210
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service